Novolin
Human Insulin · Injection, Suspension · Subcutaneous
Uses
70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Limitations of Use: In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NOVOLIN 70/30 is a mixture of human insulin isophane, an intermediate-acting human insulin, and human insulin, a short-acting human insulin, indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )
Directions
• See Full Prescribing Information for important administration instructions. ( 2.1 )
• Inject subcutaneously in abdominal wall, thigh, upper arm, or buttocks and rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.1 )
• Individualize and adjust dosage based on metabolic needs, blood glucose monitoring results and glycemic control goal. ( 2.2 )
• Inject NOVOLIN 70/30 subcutaneously approximately 30 minutes prior to start of meal. ( 2.2 )
• NOVOLIN 70/30 is typically dosed twice daily (with each dose intended to cover 2 meals or a meal and a snack). ( 2.2) 2.1 Important Administration Instructions
• Always check insulin labels before administration [see Warnings and Precautions ( 5.4 )].
• NOVOLIN 70/30 is a suspension that must be resuspended immediately before use. Resuspension is easier when the insulin has reached room temperature.
• To resuspend vial, roll the vial gently in your hands in a horizontal position 10 times until the suspension appears uniformly white and cloudy. Inject immediately.
• To resuspend FlexPen, gently move the pen up and down 20 times so the glass ball moves from one end of the cartridge to the other until the suspension appears uniformly white and cloudy. Inject immediately.
• Inspect NOVOLIN 70/30 visually before use. Do not use NOVOLIN 70/30 if discoloration or particulate matter is seen.
• Administer NOVOLIN 70/30 by subcutaneous injection in the abdominal wall, thigh, upper arm, or buttocks.
• Rotate the injection site within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] .
• During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions ( 5.2 )] .
• Do not administer NOVOLIN 70/30 intravenously and do not use in an insulin infusion pump.
• Do not mix NOVOLIN 70/30 with any other insulins or diluents. 2.2 Dosage Information
• Individualize and adjust the dosage of NOVOLIN 70/30 based on the individual’s metabolic needs, blood glucose monitoring results and glycemic control goal.
• Inject NOVOLIN 70/30 subcutaneously approximately 30 minutes before a meal.
• NOVOLIN 70/30 is typically dosed twice daily (with each dose intended to cover 2 meals or a meal and a snack).
• Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see Warnings and Precautions ( 5.2 , 5.3 ) and Use in Specific Populations ( 8.6 , 8.7 )].
• Dosage adjustment may be needed when switching from another insulin to NOVOLIN 70/30 [see Warnings and Precautions ( 5.2 )]. 2.3 Dosage Adjustment due to Drug Interactions
• Dosage adjustment may be needed when NOVOLIN 70/30 is co-administered with certain drugs [see Drug Interactions ( 7 )] .
Label text from the FDA structured product label by Novo Nordisk (revised Nov 23, 2022). Long sections are shortened; the complete label is on DailyMed.
Active ingredients
- Insulin Human in 7 products
Novolin NDC products (7)
| NDC | Strength & form | Labeler | Type |
|---|---|---|---|
| 50090-0403 | Insulin Human 100 [iU]/mL Injection, Suspension | A-S Medication Solutions | BLA |
| 0169-1833 | Insulin Human 100 [iU]/mL Injection, Solution | Novo Nordisk | BLA |
| 0169-1834 | Insulin Human 100 [iU]/mL Injection, Suspension | Novo Nordisk | BLA |
| 0169-1837 | Insulin Human 100 [iU]/mL Injection, Suspension | Novo Nordisk | BLA |
| 0169-3003 | Insulin Human 100 [iU]/mL Injection, Solution | Novo Nordisk | BLA |
| 0169-3004 | Insulin Human 100 [iU]/mL Injection, Suspension | Novo Nordisk | BLA |
| 0169-3007 | Insulin Human 100 [iU]/mL Injection, Suspension | Novo Nordisk | BLA |
Frequently asked questions
What is Novolin used for?
70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Limitations of Use: In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NOVOLIN 70/30 is a mixture of human insulin isophane, an intermediate-acting human insulin, and human insulin, a…
Who makes Novolin?
Novolin is listed by 2 labelers in the FDA NDC directory, including A-S Medication Solutions, Novo Nordisk.